Drugs / DV700P-RNA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07569029 | Jun 2026 → Aug 2027 expected | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06919016 | Aug 2025 → Mar 2027 expected | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DV700P-RNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07569029 ↗ |
| Modality | Vaccine | “This is a phase 1, first-in-human (FIH) trial for two vaccines, DV700P-RNA and DV701B1.1-RNA.” NCT06919016 ↗ |
| Route | Intramuscular | “Intramuscular injection” NCT07569029 ↗ |